about
Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study.Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa.Monocytes as a site of production of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in the septic hostEvidence of less severe aortic valve destruction after treatment of experimental staphylococcal endocarditis with vancomycin and dexamethasoneEpidemiology of infections caused by polymyxin-resistant pathogens.Effect of the novel influenza A (H1N1) virus in the human immune systemKinetics of progenitor hemopoetic stem cells in sepsis: correlation with patients survival?Antipseudomonal antibiotics.Septic arthritis due to Salmonella enteritidis associated with infliximab use.Risk factors for nasopharyngeal carriage of drug-resistant Streptococcus pneumoniae: data from a nation-wide surveillance study in Greece.Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment.Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stayDiagnostic value of triggering receptor expressed on myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational study.Ampicillin/sulbactam versus cefuroxime as antimicrobial prophylaxis for cesarean delivery: a randomized study.Promoting prudent use of antibiotics: the experience from a multifaceted regional campaign in Greece.Linezolid in prophylaxis against experimental aortic valve endocarditis due to Streptococcus oralis or Enterococcus faecalis.Plazomicin: an investigational therapy for the treatment of urinary tract infections.Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock?The association between colonization with carbapenemase-producing enterobacteriaceae and overall ICU mortality: an observational cohort studyPopulation Pharmacokinetics of Fosfomycin in Critically Ill Patients.Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial killColistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.Mycoplasma pneumoniae-associated myelitis: a comprehensive review.Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltrationLarge vessel vasculitis in a patient with acute Q-fever: A case report.Treatment options for multidrug-resistant bacteria.Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues.Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Hospital-acquired pneumonia guidelines in Europe: a review of their status and future development.Impact of an antibiotic restriction policy on the antibiotic resistance patterns of Gram-negative microorganisms in an Intensive Care Unit in Greece.Fever of unknown origin in febrile leukopenia.beta-Lactams without a suicide inhibitor.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Current therapies for pseudomonas aeruginosa.Acinetobacter baumannii: a universal threat to public health?Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trialControlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control.A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice.
P50
Q24812750-0731221C-11DF-4815-9586-9C9950BB3649Q25257156-D1289738-D447-4977-A722-EED8062F93FBQ28265940-CD3A5475-7A8F-4786-A944-483C31A1AAE2Q28364129-90300FDD-79C3-4033-899B-EB323E8E4026Q30240954-EA4DAB1D-9BC5-489C-BE2E-6BDF1713BC69Q30383946-5895F7AB-B669-4343-A4DB-C3C7D6892B23Q30823717-BF1C521D-CD0C-436B-8B2D-1E87CD9E4954Q31974278-45052B77-4547-4C46-8F51-576866A9F517Q33365363-73A5AF76-C359-49C5-A003-E20696821830Q33488329-84379777-073D-4E02-BD49-65502A3747E5Q33515785-44901FB6-A3A2-4800-9FC5-A2CFC1395314Q33520362-9CD76E75-31B9-4EA3-8DD4-D7533D341F31Q33709822-10131FBC-4049-40F2-81E7-9F856F0289A1Q33758998-68743101-1F2A-48AC-A04E-6F8A981D3965Q34107564-03CB7763-93EC-42B7-9376-621C978052B1Q34352123-66D3F594-3D88-43C2-B4D7-18F1A78512F8Q34673393-E81277C5-B953-43C5-B190-84C434F9707EQ34999537-FA8B2812-BD44-440B-B3FA-6CC154F65BE8Q35606408-BE7110B7-33E2-425B-80F5-0B7F3516916AQ36075930-29EB10A2-86B4-4464-A407-FC02030C9DF7Q36107990-B226253E-C00C-424C-9D89-29B730770CCDQ36171772-D954C740-F1DE-4144-96BF-64A13F48A520Q36290841-A64F2910-0A89-4E7E-9543-B9D6C4083DB2Q36401704-0260F33C-E321-4AFA-AC4C-F253B09A6F81Q36505428-6FDEFDBF-34F1-4534-844C-E424EC1D8009Q36604825-EF2398A5-5408-415A-8F1D-ED452E78A61DQ36607401-B189756F-DD7A-47FD-ADC7-87BB7EABE580Q36708029-30294BD2-4079-41E5-9EF3-FFA96C045DC4Q36761826-2E92B899-E00D-4822-BE3F-74232BF1B128Q36838653-9695C7AE-4E01-4D43-B070-F276201A5DF8Q36880743-5846369E-1F4B-49DF-B2F7-5CDC0CD2485BQ37025097-69F7FC53-384B-435D-81CA-4D5C2F9BDBCDQ37043649-E9F56F63-02C7-4DB0-892E-FDC09FD06D31Q37071199-91CCE714-CD1F-427B-B47F-4C5356D7C4A6Q37117212-75C76D79-7403-4494-8A59-B30528308964Q37197580-A6FE8AC2-B94C-408A-8B37-3E6E7C822A78Q37274659-D0355BD0-F98A-467F-950D-34497364AE47Q37491940-3C06264C-BB01-4B79-9163-F9683A98662AQ37677832-1C86E078-75C4-4AFF-A282-B91A37EBCA0AQ37707478-C35C3C24-79E2-4EB4-A98F-A4BABD237960
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Helen Giamarellou
@ast
Helen Giamarellou
@en
Helen Giamarellou
@es
Helen Giamarellou
@nl
Helen Giamarellou
@sl
type
label
Helen Giamarellou
@ast
Helen Giamarellou
@en
Helen Giamarellou
@es
Helen Giamarellou
@nl
Helen Giamarellou
@sl
prefLabel
Helen Giamarellou
@ast
Helen Giamarellou
@en
Helen Giamarellou
@es
Helen Giamarellou
@nl
Helen Giamarellou
@sl
P106
P1153
15743985400
P21
P31
P496
0000-0002-7387-5065
P5463
Giamarellou_Helen